Introduction: Pervious thrombi benefit more from intravenous thrombolysis, but the role of perviousness in endovascular treatment (EVT) is not completely clear. Thrombus length is negatively associated with outcome after EVT. Pervious, long thrombi may be more difficult to aspirate, or fragment more easily than non-pervious, short thrombi. We assessed the effect of perviousness and thrombus length on results of first-line aspiration thrombectomy in EVT, in comparison to stent-retrievers. Methods: We included MR CLEAN Registry patients (N=1526) with thin-slice imaging available, and aspiration or stent-retriever as first EVT attempt (N=391). Thrombus perviousness was measured by thrombus attenuation increase (Houndsfield Units; HU). Associations with 90-day modified Rankin Scale score (mRS), and final and first-pass reperfusion (eTICI 2B-3) were tested with adjusted logistic regression analyses. Results: Sixty-five (21%) patients were treated with first-line aspiration, 252 (79%) with stent-retrievers. Perviousness was not significantly associated with mRS after either first-line approach (Figure 1). Analysis per perviousness quartile did show improved mRS for stent-retrievers in the highest quartile only (>12.3 HU; acOR for mRS shift with stent-retriever treatment 3.08, 95%CI 1.06-8.96). Thrombus length was negatively associated with mRS after first-line stent-retriever thrombectomy (acOR 0.96, 95%CI 0.93-0.99). First-pass reperfusion and thrombus length were significantly, negatively associated in the first-line aspiration group (acOR 0.88, 95%CI 0.80-0.96). Conclusions: Patients with longer thrombi may show worse outcomes after both aspiration and stent-retriever thrombectomy. In patients with high perviousness values, stent-retriever thrombectomy may be related to improved outcomes as compared to first-line aspiration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.